Embedded Files
Pharmacologic Category
Central Nervous System Stimulant; Phosphodiesterase Enzyme Inhibitor, Nonselective
Dosing: Adult
Note: Caffeine citrate should not be interchanged with the caffeine sodium benzoate formulation. Dosing presented as the combination of caffeine and sodium benzoate unless otherwise noted (caffeine base amount is 50% of the caffeine and sodium benzoate combination).
Augmentation of seizure induction during electroconvulsive therapy (ECT) (off-label use): IV: Initial: 500 to 1,000 mg caffeine and sodium benzoate (equivalent to 250 to 500 mg caffeine base); if necessary during subsequent ECT sessions, may titrate dose up or down in increments of 250 to 500 mg caffeine and sodium benzoate (equivalent to 125 to 250 mg caffeine base); a maximum dose of 2,000 mg caffeine and sodium benzoate (equivalent to 1,000 mg caffeine base) during an ECT session has been reported (Coffey 1987; Hinkle 1987; McCall 1993; Shapira 1987).
Postdural puncture headache (off-label use):
IV: 500 mg caffeine and sodium benzoate (equivalent to 250 mg caffeine base) in 1,000 mL NS infused over 1 hour, followed by 1,000 mL NS infused over 2 hours; after 4 hours, a second course of caffeine can be given for unrelieved headache pain (Choi 1996; Jarvis 1986; Yucel 1999).
Oral: 300 mg (caffeine base) as a single dose (Camann 1990)
Reversal of dipyridamole- or regadenoson-induced adverse reactions (eg, angina, hypotension) during nuclear cardiac stress testing (alternative agent) (off-label use): Caffeine citrate: IV: 60 mg (diluted in 25 mL of D5W) over 3 to 5 minutes (Doran 2017; Singleton 2018)
Stimulant: OTC labeling: Oral: 100 to 200 mg (caffeine base) every 3 to 4 hours as needed
* See Dosage and Administration in AHFS Essentials for additional information.
Dosing: Geriatric
Refer to adult dosing.
Dosing: Renal Impairment: Adult
There are no dosage adjustments provided in the manufacturer's labeling. Use with caution.
Dosing: Hepatic Impairment: Adult
There are no dosage adjustments provided in the manufacturer's labeling. Use with caution.
Dosing: Pediatric
Note: Caffeine citrate should not be interchanged with the caffeine sodium benzoate formulation. Caffeine and sodium benzoate dosing presented as the combination (caffeine base amount is 50% of the caffeine and sodium benzoate combination).
Stimulant: OTC labeling: Caffeine (base): Children ≥12 years and Adolescents: Oral: 100 to 200 mg every 3 to 4 hours as needed
Dosing: Renal Impairment: Pediatric
There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied); use with caution.
Dosing: Hepatic Impairment: Pediatric
There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied); use with caution.
Use: Labeled Indications
Caffeine citrate: Treatment of idiopathic apnea of prematurity
Caffeine and sodium benzoate: See Off-Label uses.
Caffeine [OTC labeling]: Restore mental alertness or wakefulness when experiencing fatigue
* See Uses in AHFS Essentials for additional information.
Use: Off-Label: Adult
Augmentation of seizure induction during electroconvulsive therapy (caffeine and sodium benzoate)Level of Evidence [C]
Data from a randomized, double blind study as well as a few unblinded studies support the use of caffeine/sodium benzoate in the treatment of augmentation of seizure induction during electroconvulsive therapy (ECT) Ref. Additional trials may be necessary to further define the role of caffeine/sodium benzoate in this setting.
Postdural puncture headache (caffeine and sodium benzoate)Level of Evidence [B]
Data from a randomized, double blind, placebo-controlled study (Note: Second phase of study was unblinded and open-label) supports the use of IV caffeine/sodium benzoate in the treatment of postdural puncture headache Ref. One protocol for the treatment of this condition has been described Ref. Data from a double-blind, placebo-controlled trial in post-partum patients with postdural puncture headache supports the use of oral caffeine base for the treatment of this condition Ref. Additional trials may be necessary to further define the role of caffeine/sodium benzoate in this condition.
Reversal of dipyridamole- or regadenoson-induced adverse reactions (eg, angina, hypotension) during nuclear cardiac stress testing (alternative agent)Level of Evidence [C]
For dipyridamole- or regadenoson-induced adverse reactions (eg, angina, hypotension) during nuclear cardiac stress testing, when aminophylline is not available (eg, due to shortage), intravenous caffeine citrate may be used as an alternative Ref. Use of caffeine with adenosine-induced adverse reactions specifically is usually not warranted due to adenosine's short half-life (adverse reactions will usually stop within seconds of stopping adenosine) Ref.
Level of Evidence Definitions
Level of Evidence Scale
Use: Unsupported: Adult
Acute respiratory depression
Although included as an FDA-approved use in the manufacturer's prescribing information for the treatment of acute respiratory depression in the setting of overdosage with CNS depressant drugs (eg, opioids, alcohol), the use of caffeine is not recommended for this indication. Other therapies are available (eg, naloxone) for the treatment of this condition.
Administration: IV
Parenteral:
Caffeine citrate: Reversal of dipyridamole- or regadenoson-induced adverse reactions during cardiac stress testing: Infuse dose (diluted in 25 mL D5W) over 3 to 5 minutes (Doran 2017).
Caffeine and sodium benzoate: Note: Use a 0.22 micron in-line filter when administering (American Regent 2019).
Direct IV injection, administer slowly.
Postdural puncture headaches (off-label use): Infuse diluted solution over 1 hour. Follow with 1,000 mL NS infused over 2 hours (Choi 1996; Jarvis 1986; Yucel 1999).
Administration: Oral
May be administered without regard to feedings or meals. May administer injectable formulation (caffeine citrate) orally.
Administration: Pediatric
Oral: May be administered without regard to feedings or meals; may administer injectable formulation (caffeine citrate) orally
Parenteral:
Caffeine citrate: IV: May administer undiluted or further diluted with D5W. Infuse loading dose over at least 30 minutes; maintenance dose may be infused over at least 10 minutes.
Caffeine sodium benzoate: IV: Note: Use a 0.22-micron in-line filter when administering (American Regent 2019).
Direct injection: Administer slowly
Spinal headaches: Further dilute and infuse over 1 hour; follow with 1,000 mL NS infused over 2 hours (Choi 1996; Jarvis 1986)
Storage/Stability
Store at 20°C to 25°C (68°F to 77°F).
Caffeine citrate: Injection and oral solution contain no preservatives; injection is chemically stable for at least 24 hours at room temperature when diluted to 10 mg/mL (as caffeine citrate) with D5W, D50W, Intralipid® 20%, and Aminosyn® 8.5%; also compatible with dopamine (600 mcg/mL), calcium gluconate 10%, heparin (1 unit/mL), and fentanyl (10 mcg/mL) at room temperature for 24 hours.
Preparation for Administration: Adult
Parenteral:
Caffeine and sodium benzoate: Note: Perform visual inspection of vial; do not use if particulates are present. Use a 5-micron filter needle to withdraw the required volume. Remove filter needle and replace with an appropriate needle before administration or if adding to an infusion solution (American Regent 2019).
For postdural puncture headaches (off-label use), dilute in 1,000 mL NS (Jarvis 1986; Yucel 1999).
Preparation for Administration: Pediatric
Parenteral:
Caffeine citrate: May further dilute with D5W to a final concentration of 10 mg caffeine citrate/mL
Caffeine sodium benzoate: Note: Perform visual inspection of vial; do not use if particulates are present. Use a 5-micron filter needle to withdraw the required volume. Remove filter needle and replace with an appropriate needle before administration or if adding to an infusion solution (American Regent 2019).
For postdural puncture headaches, dilute in 1,000 mL NS (Jarvis 1986).
Compatibility
See Trissel’s IV Compatibility Database
Open Trissel's IV Compatibility
Extemporaneously Prepared
A 10 mg/mL oral solution of caffeine (as citrate) may be prepared from 10 g citrated caffeine powder combined with 10 g citric acid USP and dissolved in 1000 mL distilled water. Label “shake well”. Stable for 3 months at room temperature (Nahata, 2014).
A 20 mg/mL oral solution of caffeine (as citrate) may be made from 10 g citrated caffeine powder and dissolved in 250 mL sterile water for irrigation. Stir solution until completely clear, then add a 2:1 mixture of simple syrup and cherry syrup in sufficient quantity to make 500 mL. Label “shake well” and “refrigerate”. Stable for 90 days (Eisenberg, 1984).
Eisenberg MG and Kang N, "Stability of Citrated Caffeine Solutions for Injectable and Enteral Use," Am J Hosp Pharm, 1984, 41(11):2405-6.[PubMed 6507449]
Nahata MC and Pai VB, Pediatric Drug Formulations, 6th ed, Cincinnati, OH: Harvey Whitney Books Co, 2014.
Medication Patient Education with HCAHPS Considerations
What is this drug used for?
Tablets and capsules:
• It is used to make you more alert.
Frequently reported side effects of this drug
• Irritability
• Trouble sleeping
Other side effects of this drug: Talk with your doctor right away if you have any of these signs of:
• Fast heartbeat
• Severe anxiety
• Signs of a significant reaction like wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat.
Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.
Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this medicine.
Contraindications
Hypersensitivity to caffeine or any component of the formulation; sodium benzoate is not for use in neonates
Warnings/Precautions
Disease-related concerns:
• Anxiety: Avoid use in patients with anxiety, agitation, or tremor.
• Cardiovascular disease: Use with caution in patients with cardiovascular disease; avoid use in patients with symptomatic cardiac arrhythmias.
• Gastrointestinal disease: Use with caution in patients with a history of peptic ulcer and/or gastroesophageal reflux.
• Hepatic impairment: Use with caution in patients with hepatic impairment.
• Renal impairment: Use with caution in patients with renal impairment.
• Seizure disorder: Use with caution in patients with a history of seizure disorder; may lower seizure threshold leading to new onset or breakthrough seizure activity.
Special populations:
• Neonates: Caffeine citrate should be closely monitored for the development of necrotizing enterocolitis in the neonate; caffeine serum levels should be closely monitored to optimize therapy and prevent serious toxicity. Avoid use of products containing sodium benzoate in neonates; has been associated with a potentially fatal toxicity ("gasping syndrome") in neonates, including metabolic acidosis, respiratory distress, gasping respirations, seizures, intracranial hemorrhage, hypotension, and cardiovascular collapse. In vitro and animal studies have shown that benzoate also displaces bilirubin from protein-binding sites.
Dosage form specific issues:
• OTC products: OTC products contain 200 mg of caffeine per tablet approximately the amount of caffeine similar to one cup of coffee; limit the use of other caffeine-containing beverages or foods.
• Product interchangeability: Caffeine citrate should not be interchanged with caffeine and sodium benzoate.
Other warnings and precautions:
• Transcutaneous electrical nerve stimulation: Analgesia from transcutaneous electrical nerve stimulation may be lessened with concomitant caffeine use (Marchand 1995).
* See Cautions in AHFS Essentials for additional information.
Warnings: Additional Pediatric Considerations
During a caffeine citrate double-blind, placebo-controlled study, six of 85 patients developed necrotizing enterocolitis (NEC); five of these six patients had received caffeine citrate; although no causal relationship has been established, neonates who receive caffeine citrate should be closely monitored for the development of NEC. Caffeine serum levels should be closely monitored to optimize therapy and prevent serious toxicity.
The incidence of cerebellar hemorrhage was shown to be increased in patients receiving high-dose caffeine citrate (80 mg/kg total load over 36 hours) compared to those receiving standard doses (36% vs 10%) in a randomized, controlled trial in preterm neonates (n=74; GA ≤30 weeks; PNA ≤24 hours); in addition, this group also had subtle neurobehavioral differences including increased tone and abnormal movements at term equivalent age (McPherson 2015). In a post hoc analysis of this same group of neonates the high-dose group also trended towards a higher incidence of seizures (40% vs 58%; p = 0.1) and an increase in seizure duration (48.9 vs 170.9 seconds; p = 0.1) as indicated by continuous limited channel aEEG monitoring over the first 72 hours of life, although this was not statistically significant. No difference in the number of clinical seizures requiring treatment or status epilepticus were noted between the groups; also no difference in the rates of IVH, hypoglycemia or perinatal hypoxic ischemia were noted (Vesoulis 2016). Authors noted that these adverse effects discouraged the potential for a larger trial; if use deemed necessary, close monitoring is recommended (McPherson 2015; Vesoulis 2016).
Pregnancy Considerations
Caffeine crosses the placenta; serum concentrations in the fetus are similar to those in the mother (Grosso 2005).
Based on current studies, usual dietary exposure to caffeine is unlikely to cause congenital malformations (Brent 2011). However, available data show conflicting results related to maternal caffeine use and the risk of other adverse events, such as spontaneous abortion or growth retardation (Brent 2011; Jahanfar 2013; Nehlig 1994). Chronic maternal consumption of high amounts of caffeine during pregnancy may lead to neonatal withdrawal at delivery (eg, apnea, irritability, jitteriness, vomiting) (Martin 2007).
The half-life of caffeine is prolonged during the second and third trimesters of pregnancy and maternal and fetal exposure is also influenced by maternal tobacco or alcohol consumption (Brent 2011; Koren 2000). Current guidelines recommend limiting caffeine intake from all sources to ≤200 mg/day during pregnancy (ACOG 2010).
Breast-Feeding Considerations
Caffeine and its metabolites are present in breast milk (Berlin 1981; Hildebrandt 1983; Martin 2007; Oo 1995; Ryu 1985a).
Actual breast milk concentrations vary widely. The source of caffeine, how caffeinated beverages are brewed, the amount ingested, and the postpartum age of the mother affect concentrations in breast milk (Berlin 1984; Davanzo 2014; Ryu 1985b; Staychansky 1998; Tyrala 1979)
Breast milk concentrations are dependent upon maternal intake from all sources and ability to metabolize caffeine (eg, smoker versus nonsmoker) (Brent 2011). Peak breast milk concentrations generally occur within 1 to 2 hours (Berlin 1984; Calvaresi 2016; Nehlig 1994; Stavchansky 1988). In one study, caffeine was not detected in the breast milk of women ingesting <100 mg (Berlin 1984). Caffeine can be detected in the saliva and serum of some breastfed infants (Hildebrandt 1983; Ryu 1985a). The ability of the breastfeeding child to metabolize caffeine is age-dependent and higher serum concentrations are found in preterm infants (Atkinson 1988; Hildebrant 1983).
Maternal caffeine ingestion may decrease iron concentrations of breast milk (Nehlig 1994). Irritability and jitteriness have been reported in the breastfeeding infant following larger than acceptable amounts of maternal caffeine ingestion (Clement 1989; Rustin 1989). Infant heart rates and sleep patterns were not found to be affected in normal, full-term infants exposed to lesser amounts of caffeine (Ryu 1985b) or older infants (Santos 2012). Long-term effects on infant exposure have not been evaluated (O'Connor 2016).
Moderate amounts of caffeine are considered acceptable with breastfeeding (Ito 2000). Ingestion of <300 mg/day is recommended (O'Connor 2016). Caution is recommended if breastfeeding premature infants, infants small for gestational age, or if exposure to unusually high amounts of caffeine occurs (Atkinson 1988; Nehlig 1994). When maternal caffeine is from dietary sources (eg, coffee), maternal ingestion right after breastfeeding may minimize infant exposure (Calvaresi 2016).
Briggs' Drugs in Pregnancy & Lactation
Adverse Reactions
Frequency not specified; primarily serum-concentration related.
Cardiovascular: Angina pectoris, chest pain, flushing, palpitations, sinus tachycardia, supraventricular tachycardia, vasodilation, ventricular arrhythmia
Central nervous system: Agitation, delirium, dizziness, hallucination, headache, insomnia, irritability, psychosis, restlessness
Dermatologic: Urticaria
Gastrointestinal: Esophageal motility disorder (sphincter tone decreased), gastritis
Genitourinary: Diuresis
Neuromuscular & skeletal: Fasciculations
Ophthalmic: Increased intraocular pressure (>180 mg caffeine), miosis
* See Cautions in AHFS Essentials for additional information.
Metabolism/Transport Effects
Substrate of CYP1A2 (major), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (minor); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; Inhibits CYP1A2 (weak)
Drug Interactions Open Interactions
Acebrophylline: May enhance the stimulatory effect of CNS Stimulants. Risk X: Avoid combination
Adenosine: Caffeine and Caffeine Containing Products may diminish the therapeutic effect of Adenosine. Management: Monitor for decreased effect of adenosine if patient is receiving caffeine. Discontinue caffeine in advance of scheduled diagnostic use of adenosine whenever possible. Risk D: Consider therapy modification
Amifampridine: Agents With Seizure Threshold Lowering Potential may enhance the neuroexcitatory and/or seizure-potentiating effect of Amifampridine. Risk C: Monitor therapy
AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics. Risk C: Monitor therapy
Broccoli: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers). Risk C: Monitor therapy
Bromperidol: Caffeine and Caffeine Containing Products may decrease the absorption of Bromperidol. Risk C: Monitor therapy
BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential. Risk C: Monitor therapy
Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics. Exceptions: Cannabidiol. Risk C: Monitor therapy
Cannabis: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers). Risk C: Monitor therapy
CloZAPine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. Management: Drugs listed as exceptions to this monograph are discussed in further detail in separate drug interaction monographs. Risk C: Monitor therapy
Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use. Risk D: Consider therapy modification
CYP1A2 Inducers (Moderate): May decrease the serum concentration of Caffeine and Caffeine Containing Products. Risk C: Monitor therapy
CYP1A2 Inhibitors (Moderate): May increase the serum concentration of Caffeine and Caffeine Containing Products. Risk C: Monitor therapy
CYP1A2 Inhibitors (Strong): May increase the serum concentration of Caffeine and Caffeine Containing Products. Risk C: Monitor therapy
Doxofylline: Caffeine and Caffeine Containing Products may enhance the adverse/toxic effect of Doxofylline. Risk X: Avoid combination
Esketamine: May enhance the hypertensive effect of CNS Stimulants. Risk C: Monitor therapy
Formoterol: Caffeine and Caffeine Containing Products may enhance the adverse/toxic effect of Formoterol. Caffeine and Caffeine Containing Products may enhance the hypokalemic effect of Formoterol. Risk C: Monitor therapy
Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics. Risk C: Monitor therapy
Indacaterol: Caffeine and Caffeine Containing Products may enhance the adverse/toxic effect of Indacaterol. Caffeine and Caffeine Containing Products may enhance the hypokalemic effect of Indacaterol. Risk C: Monitor therapy
Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants. Risk D: Consider therapy modification
Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants. Risk D: Consider therapy modification
Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants. Risk D: Consider therapy modification
Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific dose adjustment recommendations are not presently available. Risk D: Consider therapy modification
Lithium: Caffeine and Caffeine Containing Products may decrease the serum concentration of Lithium. Risk C: Monitor therapy
Norfloxacin: May increase the serum concentration of Caffeine and Caffeine Containing Products. Risk C: Monitor therapy
Olodaterol: Caffeine and Caffeine Containing Products may enhance the adverse/toxic effect of Olodaterol. Caffeine and Caffeine Containing Products may enhance the hypokalemic effect of Olodaterol. Risk C: Monitor therapy
Pipemidic Acid: May increase the serum concentration of Caffeine and Caffeine Containing Products. Risk C: Monitor therapy
Regadenoson: Caffeine and Caffeine Containing Products may diminish the vasodilatory effect of Regadenoson. Management: Avoiding using caffeine or other methylxanthine containing products (e.g., theophylline) for at least 12 hours prior to the administration of regadenoson. Risk D: Consider therapy modification
Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Risk C: Monitor therapy
Solriamfetol: CNS Stimulants may enhance the hypertensive effect of Solriamfetol. Risk C: Monitor therapy
Stiripentol: May increase the serum concentration of Caffeine and Caffeine Containing Products. Risk X: Avoid combination
Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics. Risk C: Monitor therapy
Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics. Risk C: Monitor therapy
Theophylline Derivatives: CYP1A2 Inhibitors (Weak) may increase the serum concentration of Theophylline Derivatives. Exceptions: Dyphylline. Risk C: Monitor therapy
TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine. Management: Avoid these combinations when possible. If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions. Risk D: Consider therapy modification
Tobacco (Smoked): May decrease the serum concentration of Caffeine and Caffeine Containing Products. Risk C: Monitor therapy
Genes of Interest
Reference Range
Therapeutic: Apnea of prematurity: 8 to 20 mcg/mL
Potentially toxic: >20 mcg/mL
Toxic: >50 mcg/mL
Dosage Forms: US
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Injection, solution, as citrate [preservative free]:
Cafcit: 60 mg/3 mL (3 mL) [equivalent to 10 mg/mL caffeine base]
Generic: 60 mg/3 mL (3 mL) [equivalent to 10 mg/mL caffeine base]
Injection, solution [with sodium benzoate]:
Generic: Caffeine 125 mg/mL and sodium benzoate 125 mg/mL (2 mL)
Solution, oral, as citrate [preservative free]:
Cafcit: 60 mg/3 mL (3 mL) [equivalent to 10 mg/mL caffeine base] [DSC]
Generic: 60 mg/3 mL (3 mL) [equivalent to 10 mg/mL caffeine base]
Tablet, oral:
Keep Alert: 200 mg
NoDoz Maximum Strength: 200 mg [DSC]
Stay Awake: 200 mg
Stay Awake Maximum Strength: 200 mg
Vivarin: 200 mg
Generic: 200 mg
Anatomic Therapeutic Chemical (ATC) Classification
- N06BC01
Generic Available (US)
Yes: Tablet, caffeine and sodium benzoate injection, injection, oral solution
Pricing: US
Solution (Cafcit Intravenous)
60 mg/3 mL (per mL): $14.00
Solution (Caffeine Citrate Intravenous)
60 mg/3 mL (per mL): $3.26 - $14.00
Solution (Caffeine Citrate Oral)
60 mg/3 mL (per mL): $8.00 - $9.60
Solution (Caffeine-Sodium Benzoate Injection)
125-125 mg/mL (per mL): $11.49
Tablets (Caffeine Oral)
200 mg (per each): $0.11
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Mechanism of Action
Increases levels of 3'5' cyclic AMP by inhibiting phosphodiesterase; CNS stimulant which increases medullary respiratory center sensitivity to carbon dioxide, stimulates central inspiratory drive, and improves skeletal muscle contraction (diaphragmatic contractility); prevention of apnea may occur by competitive inhibition of adenosine
Pharmacodynamics/Kinetics
Distribution: Vd:
Neonates: 0.8 to 0.9 L/kg
Children >9 months to Adults: 0.6 L/kg
Protein binding: 17% (children) to 36% (adults)
Metabolism: Hepatic, via demethylation by CYP1A2. Note: In neonates, interconversion between caffeine and theophylline has been reported (caffeine levels are ~25% of measured theophylline after theophylline administration and ~3% to 8% of caffeine would be expected to be converted to theophylline)
Half-life elimination:
Neonates: 72 to 96 hours (range: 40 to 230 hours)
Children >9 months and Adults: 5 hours
Time to peak, serum: Oral: Within 30 minutes to 2 hours
Excretion:
Neonates ≤1 month: 86% excreted unchanged in urine
Infants >1 month and Adults: In urine, as metabolites
Clearance:
Neonates: 8.9 mL/hour/kg (range: 2.5 to 17)
Adults: 94 mL/hour/kg
Pharmacodynamics/Kinetics: Additional Considerations
Pregnancy and cirrhosis: Half-life is increased.
Local Anesthetic/Vasoconstrictor Precautions
No information available to require special precautions
Effects on Dental Treatment
Key adverse event(s) related to dental treatment: Caffeine causes tachycardia, increases in blood pressure, and palpitations. Consider monitoring blood pressure prior to using local anesthetic with a vasoconstrictor. Symptoms associated with bruxism have been observed in some patients.
Effects on Bleeding
No information available to require special precautions
Index Terms
Caffeine and Sodium Benzoate; Caffeine Citrate; Caffeine Sodium Benzoate; Sodium Benzoate and Caffeine
FDA Approval Date
September 21, 1999
References
American College of Obstetricians and Gynecologists, "ACOG Committee Opinion No. 462: Moderate Caffeine Consumption During Pregnancy," Obstet Gynecol, 2010, 116(2 Pt 1):467-8.[PubMed 20664420]
American Regent. Product safety bulletin. Important drug administration information: caffeine and sodium benzoate injection, USP, 250 mg/mL (125 mg/mL caffeine) 2 mL single dose vials. American Regent website. https://www.americanregent.com/media/2117/caffeine-sodium-benzoate-drug-infomation-notice-dicsb-rev-4-19.pdf. Published April 2019.
Anderson PO, Sauberan JB. Modeling drug passage into human milk. Clin Pharmacol Ther. 2016;100(1):42-52.[PubMed 27060684]
Atkinson HC, Begg EJ, Darlow BA. Drugs in human milk. Clinical pharmacokinetic considerations. Clin Pharmacokinet. 1988;14(4):217-240.[PubMed 3292101]
Berlin CM Jr, Denson HM, Daniel CH, Ward RM. Disposition of dietary caffeine in milk, saliva, and plasma of lactating women. Pediatrics. 1984;73(1):59-63.[PubMed 6691042]
Berlin CM Jr, "Excretion of Methylxanthines in Human Milk," Semin Perinatol, 1981, 5(4):389-94.[PubMed 7302615]
Bhatt-Mehta V and Schumacher RE, “Treatment of Apnea of Prematurity,” Paediatr Drugs, 2003, 5(3):195-210.[PubMed 12608884 ]
Brent RL, Christian MS, Diener RM. Evaluation of the reproductive and developmental risks of caffeine. Birth Defects Res B Dev Reprod Toxicol. 2011;92(2):152-87.[PubMed 21370398 ]
Cafcit injection (caffeine) [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; February 2015.
Caffeine and sodium benzoate injection [prescribing information]. Shirley, NY: American Regent, Inc; September 2008.
Caffeine citrate injection, oral solution (caffeine) [prescribing information]. Lenoir NC: Exela Pharma Sciences; 2015.
Calvaresi V, Escuder D, Minutillo A, et al. Transfer of nicotine, cotinine and caffeine into breast milk in a smoker mother consuming caffeinated drinks. J Anal Toxicol. 2016;40(6):473-477.[PubMed 27129353]
Camann WR, Murray RS, Mushlin PS, Lambert DH. Effects of oral caffeine on postdural puncture headache. A double-blind, placebo-controlled trial. Anesth Analg. 1990;70(2):181-184.[PubMed 2405733]
Choi A, Laurito CE, and Cunningham FE, “Pharmacologic Management of Postdural Puncture Headache,” Ann Pharmacother, 1996, 30(7-8):831-9.[PubMed 8826568]
Clement MI. Personal view: caffeine and babies. Br Med J. 1989;298:1461.
Coffey CE, Weiner RD, Hinkle PE, Cress M, Daughtry G, Wilson WH. Augmentation of ECT seizures with caffeine. Biol Psychiatry. 1987;22(5):637-649.[PubMed 3580438]
Davanzo R, Bua J, Paloni G, Facchina G. Breastfeeding and migraine drugs. Eur J Clin Pharmacol. 2014;70(11):1313-1324.[PubMed 25217187]
Doran JA, Sajjad W, Schneider MD, Gupta R, Mackin ML, Schwartz RG. Aminophylline and caffeine for reversal of adverse symptoms associated with regadenoson SPECT MPI. J Nucl Cardiol. 2017;24(3):1062-1070. doi: 10.1007/s12350-016-0452-0.[PubMed 27025843]
Erenberg A, Leff RD, Haack DG, et al, “Caffeine Citrate for the Treatment of Apnea of Prematurity: A Double-Blind, Placebo-Controlled Study,” Pharmacotherapy, 2000, 20(6):644-52.[PubMed 10853619]
Fratto G, Manzon L. Use of psychotropic drugs and associated dental diseases. Int J Psychiatry Med. 2014;48(3):185-197.[PubMed 25492713]
Gray PH, Flenady VJ, Charles BG, Steer PA; Caffeine Collaborative Study Group. Caffeine citrate for very preterm infants: Effects on development, temperament and behaviour. J Paediatr Child Health. 2011;47(4):167-172.[PubMed 21244548]
Grosso LM, Bracken MB. Caffeine metabolism, genetics, and perinatal outcomes: a review of exposure assessment considerations during pregnancy. Ann Epidemiol. 2005;15(6):460-6.[PubMed 15967394 ]
Henzlova MJ, Duvall WL, Einstein AJ, Travin MI, Verberne HJ. ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers [published correction appears in: J Nucl Cardiol. 2016;23(3):640-642.]. J Nucl Cardiol. 2016;23(3):606-639. doi: 10.1007/s12350-015-0387-x.[PubMed 26914678]
Hildebrandt R and Gundert-Remy U, "Lack of Pharmacological Active Saliva Levels of Caffeine in Breast-Fed Infants," Pediatr Pharmacol, 1983, 3(3-4):237-44.[PubMed 6677875]
Hinkle PE, Coffey CE, Weiner RD, Cress M, Christison C. Use of caffeine to lengthen seizures in ECT. Am J Psychiatry. 1987;144(9):1143-1148.[PubMed 3631312]
Ito S. Drug therapy for breast-feeding women. N Engl J Med. 2000;343(2):118-126.[PubMed 10891521]
Jahanfar S, Jaafar SH. Effects of restricted caffeine intake by mother on fetal, neonatal and pregnancy outcome. Cochrane Database Syst Rev. 2013;2:CD006965.[PubMed 23450573 ]
Jarvis AP, Greenawalt JW, Fagraeus L. Intravenous caffeine for postdural puncture headache. Anesth Analg. 1986;65(3):316-317.[PubMed 3954102]
Koren G, “Caffeine During Pregnancy? In Moderation,” Can Fam Physician, 2000, 46(4):801-3.[PubMed 10790810]
Kriter KE and Blanchard J, “Management of Apnea in Infants,” Clin Pharm, 1989, 8(8):577-87.[PubMed 2670399]
Marchand S, Li J, Charest J. Effects of caffeine on analgesia from transcutaneous electrical nerve stimulation. N Engl J Med. 1995;333(5):325-326.[PubMed 7596392]
Martín I, López-Vílchez MA, Mur A, et al, "Neonatal Withdrawal Syndrome After Chronic Maternal Drinking of Mate," Ther Drug Monit, 2007, 29(1):127-9.[PubMed 17304161]
Maximum Strength Stay Awake tablet (caffeine) [prescribing information]. Pleasanton, CA: Safeway Inc; July 2013.
McCall WV, Reid S, Rosenquist P, Foreman A, Kiesow-Webb N. A reappraisal of the role of caffeine in ECT. Am J Psychiatry. 1993;150(10):1543-1545.[PubMed 8379563]
McPherson C, Neil JJ, Tjoeng TH, Pineda R, Inder TE. A pilot randomized trial of high-dose caffeine therapy in preterm infants. Pediatr Res. 2015;78(2):198-204.[PubMed 25856169]
Mohammed S, Nour I, Shabaan AE, Shouman B, Abdel-Hady H, Nasef N. High versus low-dose caffeine for apnea of prematurity: a randomized controlled trial. Eur J Pediatr. 2015;174(7):949-956.[PubMed 25644724]
Nehlig A, Debry G. Consequences on the newborn of chronic maternal consumption of coffee during gestation and lactation: a review. J Am Coll Nutr. 1994;13(1):6-21.[PubMed 8157856]
Nodoz Maximum Strength Alertness Aid tablet (caffeine) [prescribing information]. Parsippany, NJ: Novartis Consumer Health, Inc; December 2009.
O'Connor DL, Blake J, Bell R, et al. Canadian consensus on female nutrition: adolescence, reproduction, menopause, and beyond. J Obstet Gynaecol Can. 2016;38(6):508-554.[PubMed 27368135]
Oo CY, Burgio DE, Kuhn RC, Desai N, McNamara PJ. Pharmacokinetics of caffeine and its demethylated metabolites in lactation: predictions of milk to serum concentration ratios. Pharm Res. 1995;12(2):313-316.[PubMed 7784352]
Rustin J. Personal view: caffeine and babies. Br Med J. 1989;299:121.
Ryu JE, "Caffeine in Human Milk and in Serum of Breast-Fed Infants," Dev Pharmacol Ther, 1985a, 8(6):329-37.[PubMed 4075932]
Ryu JE, "Effect of Maternal Caffeine Consumption on Heart Rate and Sleep Time of Breast-Fed Infants," Dev Pharmacol Ther, 1985b, 8(6):355-63.[PubMed 4075934]
Santos IS, Matijasevich A, Domingues MR. Maternal caffeine consumption and infant nighttime waking: prospective cohort study. Pediatrics. 2012;129(5):860-868.[PubMed 22473365]
Schmidt B, Roberts RS, Davis P, et al.; Caffeine for Apnea of Prematurity Trial Group. Caffeine therapy for apnea of prematurity. N Engl J Med. 2006;354(20):2112-2121.[PubMed 16707748]
Schmidt B, Roberts RS, Davis P, et al.; Caffeine for Apnea of Prematurity Trial Group. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med. 2007;357(19):1893-1902.[PubMed 17989382]
Sechzer PH, Abel L. Post-spinal anesthesia headache treated with caffeine. Evaluation with demand method. Part I. Current Therapeutic Research. 1978;24(3):307-312.
Shapira B, Lerer B, Gilboa D, Drexler H, Kugelmass S, Calev A. Facilitation of ECT by caffeine pretreatment. Am J Psychiatry. 1987;144(9):1199-1202.[PubMed 3631318]
Singleton EL, Le N, Ness GL. Theophylline and caffeine as alternatives during an aminophylline shortage [published online ahead of print October 11, 2018]. Ann Pharmacother. doi: 10.1177/1060028018806624.[PubMed 30304941]
Stavchansky S, Combs A, Sagraves R, Delgado M, Joshi A. Pharmacokinetics of caffeine in breast milk and plasma after single oral administration of caffeine to lactating mothers. Biopharm Drug Dispos. 1988;9(3):285-299.[PubMed 3395670]
Stay Awake tablet (caffeine) [prescribing information]. Hauppauge, NY: LNK International, Inc; January 2015.[PubMed 17989382]
Steer P, Flenady V, Shearman A, et al.; Caffeine Collaborative Study Group Steering Group. High dose caffeine citrate for extubation of preterm infants: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. 2004;89(6):F499-503.[PubMed 15499141]
Tyrala EE and Dodson WE, "Caffeine Secretion Into Breast Milk," Arch Dis Child, 1979, 54(10):787-9.[PubMed 507903]
Vesoulis ZA, McPherson C, Neil JJ, Mathur AM, Inder TE. Early high-dose caffeine increases seizure burden in extremely preterm neonates: a preliminary study. J Caffeine Res. 2016;6(3):101-107.[PubMed 27679737]
Vivarin tablet (caffeine) [prescribing information]. Atlanta, GA: Meda Consumer Healthcare Inc; May, 2014.
Yücel A, Ozyalçin S, Talu GK, Yücel EC, Erdine S. Intravenous administration of caffeine sodium benzoate for postdural puncture headache. Reg Anesth Pain Med. 1999;24(1):51-54.[PubMed 9952095]
Brand Names: International
Cafcit (GR, VN); Cafnea (AU); Coffeinum Natrium Benzoicum (PL); Kofex (PL); NeoCaf (KR); Peyona (IE, NO, RO)
Last Updated 3/10/20
Google Sites
Report abuse